Navigation Links
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Date:4/27/2009

ced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the rate of objective tumor response for the expansion stage of this trial will not be consistent with the objective tumor response experienced in the first stage of the trial and the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
6. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
7. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
8. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
11. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 The ETC (Emerging ... technology innovation centers, announced today that applications for ... December 1st. “Do you have a big idea?,” ... want to know about it. AccelerateBaltimore helps you ... product in just 13 weeks.” Interested game ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to announce ... (New Jersey) Chamber of Commerce as a member. ... in the North Jersey area, offers Whitehouse Laboratories ... clients in the pharmaceutical and biotechnology areas that ... enables Whitehouse Laboratories a higher level of visibility ...
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... 2014 The Pittcon marketing department is ... and exposition mobile app, Pittcon 2015 ... the App Store for iOS and Android devices and ... before, during and after the event. It acts as ... companies, technical sessions, Conferee Networking sessions and short courses. ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Pittcon Releases 2015 Mobile App 2
... Technologies, an emerging,leader in the development of implantable ... today the addition of Jon Tremmel to its,Board ... after nearly 30 years of service,Jon held a ... the,Neurological Division, President of the Physio-Control Division, President,of ...
... of promoted products and reduced operating costs drive solid ... ... WCRX ) today announced its results for the quarter ended,March 31, ... increase of 5.1%, over the prior year quarter. The primary,drivers of the ...
... ,EUSA Pharma Inc (,EUSA,), a transatlantic specialty pharmaceutical ... today announced that,it has completed its acquisition of ... a special meeting on 8 May., Under ... will,receive $0.62 per share, valuing the company at ...
Cached Biology Technology:InSet Technologies Appoints Jon Tremmel to its Board of Directors 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 3Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 4Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 5Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 6Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 7Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 8Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 9Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 10Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 11Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 12Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 13Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 14Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 15Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 16Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 17EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/5/2014)... Janeiro, Brazil -Individuals show great diversity in their ability ... and females greatly differ in their perceptual evaluation of ... smell tests. , Sex differences in olfactory ... and may be connected to one,s perception of smell, ... Thus, women,s olfactory superiority has been suggested to be ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... RENO, Nev. Like the little engine that could, ... sludge to electrical power is chugging along, dwarfed by ... Meadows Water Reclamation Facility where, ultimately, the plant,s electrical ... researchers are developing. "We are very pleased with ...
... French . Treatment with vitamin C rapidly ... a study carried out by researchers at Montreal,s Jewish General ... Research (LDI). In a double-blind clinical trial, patients admitted ... C or vitamin D supplements for seven to ten days. ...
... A committee of the National Academy of Engineering ... of the causes of the Deepwater Horizon explosion and ... from Mark Bly, group head of safety and operations ... released accident investigation report. Also on the agenda ...
Cached Biology News:University of Nevada, Reno demonstrates successful sludge-to-power research 2University of Nevada, Reno demonstrates successful sludge-to-power research 3Vitamin C rapidly improves emotional state of acutely hospitalized patients, say LDI researchers 2
... the yolk protein Vtg in plasma from juvenile ... biomarker for endocrine disrupting chemicals (EDCs) with estrogenic ... an accepted screening test for the estrogenic effects ... EIA kit is a double-antibody immunometric (sandwich) EIA ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
... PEP-152 is a 17 amino acid synthetic peptide whose sequence ... is (amino to carboxy terminus): C - N(217) - Q ... S - A - T - P - N - Y ... peptide may be used for neutralization and control experiments with the ...
... of IgY) , After we receive your antigen ... the appropriate number of chickens and begin to ... collected (usually over a period of 3-5 days), ... total of four injections into the breast muscle. ...
Biology Products: